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Summary 
To search for possible ligands of CD2 distinct from CD58 (lymphocyte function-associated antigen 
3), we have produced a soluble pentameric CD2-immunoglobulin (Ig) fusion protein (spCD2) 
linking the 182-amino acid human CD2 extracellular  segment with CH2-CH3-CH4 domains 
of human IgM heavy chain, thus enhancing the micromolar affinity of the CD2 monomer through 
multimeric interaction. Using quantitative immunofluorescence and standard stringency wash 
conditions, we observed that the binding of spCD2 to human B lymphoblastoid JY cells and 
red blood cells is virtually inhibited by anti-CD58 TS2/9 monoclonal antibody, even though 
these cells express levels of CD48 and CD59 comparable to CD58. Consistent with these results, 
spCD2 did not show any binding to Chinese hamster ovary (CHO) cells transfected with human 
CD48 or CD59. However, binding studies on CD48-, CD58-, or CD59-transfected CHO cells 
with spCD2 under low stringency wash conditions revealed that human CD48 is a low affinity 
ligand of human CD2 compared with CD58  (Kd  '~10 -4 vs.  "~10  -6 M,  respectively).  The 
findings are noteworthy given that in the murine system CD48 is the major ligand for CD2. 
No detectable binding was observed to CD59-transfected CHO cells despite a report suggesting 
that CD59 may bind to the human CD2 adhesion domain. Importantly, in cell-cell  adhesion 
assays between CD2 § Jurkat T cells and CD48- or CD59-transfected CHO cells, there was no 
conjugate formation, whereas binding of Jurkat T  cells to CD58-transfected CHO cells was 
readily detected. Collectively, our findings provide evidence for a conservation of the CD2-CD48 
interaction in the human species that may be of limited, if any, functional significance￿9 Given 
the importance of the CD2-CD48 interaction in the murine system and CD2-CD58 interaction 
in humans, it would appear that there has been a divergence of functional CD2 ligands during 
the evolution of humans and mice. 
T 
he CD2 molecule on T lymphocytes is a transmembrane 
surface glycoprotein that facilitates cell-cell contact (1-3). 
The amino-terminal domain of CD2 (domain 1) mediates 
its adhesion function by binding to LFA-3 (CD58) (3), an- 
other cell surface glycoprotein widely expressed on various 
cell types, including hematopoietic and epithelial cells (4). 
Both CD2 and CD58 are members of the Ig gene superfam- 
ily (5). The importance of CD2 function in the normal human 
response has been well documented: (a) for the process of 
cognate recognition involving Th cells and APC (6, 7); (b) 
for the cytolytic effector function of NK cells and CTL (8, 
9); and (c) as a basis of the thymocyte-thymic epithelial cell 
interaction (10, 11). Moreover, in T lymphocytes perturba- 
tion of the extracellular segment of CD2 with specific mAbs 
leads to activation via a TCR-dependent mechanism (12, 13). 
Also, engagement of CD2 by its ligand CD58 together with 
mAbs specific for the membrane proximal second domain 
of CD2 (domain 2) can activate T cells (14), indicating that 
coordinate binding of ligands  to  both  domains  of CD2 
generates  an intracellular  activation signal. 
Whether there are other ligands of CD2 domain 1 or any 
natural ligands of CD2 domain 2 is presently uncertain. How- 
1439  j.  Exp.  Med.  ￿9  The Rockefeller  University Press ￿9 0022-1007/93/05/1439/12  $2.00 
Volume 177  May 1993  1439-1450 ever,  in view of known alternative ligands  of the integrin 
receptor LFA-1 (15-17) as well as the Ig supergene family 
receptors intercellular  adhesion molecule type 1 (ICAM-1) 
(15, 18) and B7 (19, 20), this is a distinct possibility. To search 
for CD2 ligands distinct from CD58, we have produced a 
pentameric form of soluble CD2 (spCD2) 1 as a probe. This 
protein is a fusion product comprising the entire 182-amino 
acid (aa) extracellular  segment of human CD2 and the CH2, 
CH3, and CH4 domains of the human/~  heavy chain.  The 
avidity of this multimeric CD2 construct overcomes the low 
(micromolar)  affinity of the monomeric CD2 extracellular 
segment for its ligand(s) and makes it possible to utilize the 
extracellular  CD2 segment as a probe to define alternative 
ligands. 
Analysis of the binding of biotinylated spCD2 to JY cells 
and other B lymphoblastoid, monocytic, and erythroleukemic 
cell lines showed a striking  correlation between CD58 ex- 
pression and spCD2 binding: all spCD2 binding cells expressed 
CD58 and were inhibited from binding spCD2 by anti-CD58 
mAb. Since human CD48 is structurally related to CD58, 
sharing 31% aa identity (21), and it has been clearly demon- 
strated that the major ligand of CD2 is CD48 in the murine 
system (22), we examined the ability of human CD48 to bind 
to human  CD2.  Not surprisingly,  we were able to detect 
binding of spCD2 to human CD48.  However, we observe 
that in contrast to the CD2-CD58 interaction,  which pro- 
motes cell-cell adhesion, the CD2-CD48 interaction fails to 
support functional conjugates between CD2 + T  cells  and 
CD48-expressing cells and is characterized by an •100-fold 
weaker affinity. A third possible CD2 ligand, CD59 (23, 24), 
was not confirmed in either cell-based or spCD2-based binding 
assays. 
Materials and Methods 
mAbs 
The following previously described murine mAbs to human an- 
tigens were used. TS2/9 (anti-CD58,  IgG1) (25) was generously 
provided by Dr. T. Springer (Center for Blood Research, Boston, 
MA). 3T4-8B5  (anti-Till,  IgG2a)  (12), 1 mono2A6  (anti-Tll3, 
IgG3) (12), 7T4-7A9 (anti-Tilt,  IgM), 2Ad2A2 (anti-CD3, IgM), 
and an anticlonotypic mAb 11C5 (IgG1) were derived in our labo- 
ratory. H19 (anti-CD59,  IgG2a) (26) was provided by Dr. A. Ber- 
nard (Centre Hospitalier, Universitaire de Nice, France). YTH.53.1 
(anti-CD59, rat IgGb) (27) was a gift from Dr. H. Waldmann (Ox- 
ford University, Oxford, England),  and 6.28 (anti-CD48,  IgG3) 
(28) was provided by Dr.  D. Thorley Lawson (Tufts University, 
Medford, MA). mAb 133-7 (anti-human B7, IgM) (29) was kindly 
provided by Dr. L. Nadler (Dana-Farber Cancer Institute, Boston, 
MA) and used as a control IgM for SDS-PAGE. 
Construction and Expression of Recombinant spCD2 
An 8-kb BamHI/HindlII genomic fragment containing  the C 
region oflgM heavy chain was exrised from pN4b.u, trinitrophenyl 
Abbreviations  used  in this  paper: aa, amino acid; spCD2, soluble  pentameric 
CD2. 
(TNP) (30), which was a gift from Dr. M. Schulman (University 
of Toronto,  Canada),  and cloned into BamHI/HindlII-digested 
Bluescript II KSM13 + (Stratagene, La Jolla, CA). Most of the 5' 
sequences upstream of exon 1 were eliminated by linearizing the 
plasmid with  HindlII,  digesting  with Ba131 nuclease, and  gel 
purification of a 2-kb fragment containing  all exons of the C re- 
gion of IgM. This fragment  was digested with XbaI to remove 
the exon encoding the transmembrane region and was subcloned 
into the XbaI site of pBluescript II KS(+), which lies adjacent to 
a BamHI and HindlII site. A 600-bp BamHI fragment ofpAC373/ 
Tl1,~2 (31) was cloned into the BamHI site of this plasmid. The 
HindlII/XbaI fragment of the resulting chimeric plasmid was then 
subcloned into M13mp19 digested with HindlII/XbaI. Oligonu- 
deotide-mediated  mutagenesis was then conducted with the syn- 
thetic nucleotide 5'-CACTTTGGGAGC~AGCTCAGCAATCAC- 
TTTCTCTGGACAGCTGACAGGCTCGAC-Y  to loop out se- 
quences (including  CH1 exon 1 of/~ heavy chain), between the 
last Tl1~2 codon coding for lysine 182 and the first codon of CH2 
encoding for valine. The sequence of the junction after mutagenesis 
was confirmed by dideoxy sequencing. The BamHI fragment con- 
taining the chimeric CD2-IgM gene was excised, blunt ended with 
klenow, and inserted into the XhoI site of the mammalian expres- 
sion vector pM2 (M. Concino, unpublished results) in the appro- 
priate orientation  resulting  in the plasmid pM2CD2IgM. 
pM2CD2IgM and pSV2 dhfr (32) were linearized with Fspl 
and  then  contransfected  into  CHO-dhfr-  cells provided by L. 
Chasin (Columbia University, New York, NY) using the calcium 
phosphate method of DNA precipitation at a ratio of 25:1 #g, respec- 
tively. Transfectants were selected in ribo- and deoxyribonucleoside- 
deficient ot-MEM (Media Tech, Inc., Herndon, VA) supplemented 
with 10% dialyzed FCS. CHO cells expressing spCD2 were pas- 
saged two to three  times in selective media containing  20 mM 
methotrexate  (MTX; Sigma Chemical Co., St. Louis, MO). Sur- 
vivors were assayed for spCD2 expression by testing supernatants 
with an alkaline phosphatase-conjugated  goat anti-human  IgM 
antibody (Southern Biotechnology Associates, Birmingham,  AL) 
by sandwich ELISA on plates coated with anti-Till  mAb, 3T4- 
8B5. Positives were passaged at least three times in 50 mM MTX 
and tested each time for spCD2 secretion, and one stable secretor 
clone was expanded for the purification of spCD2. 
Purification and Biotinflation of spCD2 and sCD2 
spCD2 was purified by immunoatfinity chromatography  on an 
anti-Till  (3T4-SB5) mAb-coupled Sepharose 4B column.  CHO- 
derived culture supernatant containing spCD2 was passed through 
a column equilibrated with PBS, pH 7.4,  and the column was 
washed extensively with PBS. The bound material was eluted with 
0.2 M glycine-HC1, pH 2.7, and 2-ml fractions collected into tubes 
containing 0.5 ml I M Tris base, pH 9.0, were subsequently pooled 
and concentrated up to I mg/ml on a centriprep-10 (Amicon Corp., 
Danvers, MA). Biotinylation of spCD2 was conducted by adding 
3.4  /~g of N-hydroxysuccinamide-long  chain  (NHS-LC)  biotin 
(Pierce Chemical Co., Rockford, IL) to 100/xg of spCD2 in PBS, 
pH 7.4, in a reaction volume of 100/~1, and incubating  this mix- 
ture for I h at room temperature. The reaction was quenched by 
adding 5/~1 of 1 M Tris/HC1, pH 7.4. A plasmid encoding mono- 
meric sCD2 was expressed in CHO cells and purified on an anti- 
Tlll (3T4-8BS) column as previously described (33). sCD2 was 
biotinylated by adding  143 #g of NHS-LC biotin to 500 #g of 
sCD2 (10:1 molar ratio) and incubating the mixture for I h at room 
temperature and subsequently quenching the reaction with 10 #1 
of 1 M Tris/HC1,  pH 7.4. 
1440  CD2-mediated  Cell-Cell Adhesion via CD58 but Not CD48 or CD59 Cells and Media 
The following human cell lines were used in this study: J77, 
JY, SLA, Arent, Daudi, Kaji, K562, U937, and HL60, which were 
cultured in ILPMI 1640 (Gibco Laboratories,  Grand Island,  NY) 
containing 10% FCS (Sigma Chemical Co.), 1% glutamine, 1% 
penicillin-streptomycin  (Gibco Laboratories), and 1% sodium pyru- 
vate (Whittaker Bioproducts, Walkersville,  MD).  Human KBC 
were isolated from normal healthy blood donors (Blood Bank, Dana- 
Farber Cancer Institute). CHO cells expressing either CD59 or 
CD58 and CD59 were obtained from Dr. A. Bernard and cultured 
in Ham's F12 media as described previously (34).  Untransfected 
CHO cells were cultured in media containing equal amounts of 
F12 nutrient mixture (Gibco Laboratories) and DME (Whittaker 
Bioproducts),  10%  FCS  (Sigma  Chemical Co.),  1% penicillin- 
streptomycin, 1% glutamine, and 1% Hepes buffer (Gibco Labora- 
tories). Trypsin-EDTA (Gibco Laboratories) was used to remove 
adherent CHO ceils from culture flasks. 
Flow Cytometric Analysis 
spCD2 Binding.  2  x  10  s cells were routinely incubated with 
50 #1 of 10 #g/ml biotinylated spCD2 for 30 min at 4~  For 
blocking studies with inhibitors, cells were pretreated with 40 #1 
of a 1:100 dilution of mAb ascites and in some cases, 1-2 mg/ml 
purified mAbs or 2 mg/ml concentration of sCD2 or sCD4 (35) 
for 1 h at 4~  before the addition of biotinylated spCD2. Subse- 
quently, cells were washed once with wash media (HBSS containing 
2% FCS), and 50 #1 of a 1:25 dilution of streptavidin-FITC (Caltag 
Labs, So. San Francisco, CA) was added and incubated further for 
20 min at 4~  Cells were washed once, fixed in a PBS solution 
containing 3.7%  formaldehyde, and fluorescence  was  estimated 
using a flow cytometer. 
spCD2 Binding under  a Low Stringency Wash Condition.  4  x  10  s 
cells were incubated with 50 #1 of 10 #g/ml biotinylated spCD2 
for 1 h at 4~  For titration of spCD2, various concentrations of 
biotinylated spCD2 ranging from 0.01 to 100 #g/m1 were used. 
For blocking experiments either biotinylated spCD2 was prein- 
cubated with 10 #g/m1 anti-Till F(ab')z or anti-T113 F(ab')z, or in 
,some cases cells were preincubated with a 1:50 dilution of mAb 
ascites or 20 #g/ml purified mAb directed against cell surface mol- 
ecules for 1 h at 4~  before the addition of spCD2. At the end 
of the 1-h incubation, cells were spun down and flicked once to 
remove most of the unbound spCD2, and 50 #1 of 1:20 dilution 
of FITC-conjugated Streptavidin (Caltag Labs) was added directly 
without washing the cells. After a further 1-h incubation at 4~ 
cells were spun down after mixing with 150 #1 of media and ana- 
lyzed immediately on a FACScan  |  (Becton Dickinson & Co., Moun- 
tain View, CA). 
mAb Binding.  2  x  105 cells were incubated with 50 #1 of ei- 
ther 1:100 dilution of mAb ascites or 10 #g/ml of purified mAbs 
for 30 min at 4~  washed once as described above, and analyzed 
by indirect immunostaining using fluoresceinated  second-step re- 
agents. 50 #I of a 1:50 dilution of FITC-conjugated goat anti-mouse 
Ig (Whittaker Bioproducts) or goat anti-rat Ig (Caltag Labs) was 
added and incubated for 20 min at 4~  Subsequently, cells were 
washed once in wash media and fixed in formaldehyde as described 
above,  and  cell-bound  fluorescence  was  analyzed using  a  flow 
cytometer. 
Binding of Radioiodinated sCD2 to JY Cells 
100/xg of sCD2 was radioiodinated by the solid phase lactoperox- 
idase/glucose oxidase (Enzyrnobeads; Bio-Rad Laboratories,  Rich- 
mond, CA) method as described previously (31). For the cold com- 
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petition assay, 5  x  106 cpm of l~SI-sCD2 at 0.125 #M in 50 #l 
(3.1  x  108 cpm/nmol) was added to 2  x  106 JY cells preincubated 
with either increasing concentrations of cold sCD2 (0.025-12.5 
#M) or a 1:50 dilution ofTS2/9 anti-CD58 mAb ascites in a final 
volume of 200 #1, which had been previously overlayed onto 0.2 
ml of a 1.5:1 mixture of dibutyl phthalate/dioctyl phthalate (Al- 
drich Chemical Co., Milwaukee,  WI) in 0.5-ml plastic microcen- 
trifuge tubes (Sarstredt,  Numbrecht, Germany). After a 1-h incu- 
bation at 4oC, the tubes were centrifuged in a microfuge (152; 
Beckman Instrs., Inc., Fullerton, CA) for 2 min, and tips of tubes 
containing cell pellets were cut and cell bound radioactivity was 
determined in a gamma counter. 
Transfection of CD58 and CD48 into ClIO Cells 
CD58 cDNA in expression vector CDM8 was a gift from Dr. 
B. Seed (Massachusetts General Hospital, Boston, MA) (36). CD48 
cDNA in expression vector CDM8 was provided by Dr. D. Thorley- 
Lawson (Tufts University, Boston, MA) (37). Plasmid DNAs were 
purified by the Qiagen column method according to the manufac- 
turer's recommendations  (Qiagen, Studio City, CA). 50 #g of KpnI- 
linearized CD58-CDM8 or CD48-CDM8 was cotransfected with 
5 #g of PvuI-linearized pSV2-neo-Sp65  (38) into CHO ceils by 
electroporation using an electroporator (Bethesda Research Labora- 
tories, Bethesda, MD) at settings of 250 V and 1,600 #F (39). Trans- 
fectants were selected in growth media containing 400 #g/ml G418 
and screened  for expression  of CD58 or CD48 by indirect im- 
munofluorescence using anti-CD58 or anti-CD48 mAbs.  Stable 
CHO cell lines expressing comparable levels of CD58 or CD48, 
now termed CHO-CD58 and CHO-CD48, were established  by 
cell sorting on an Epics V flow cytometer. 
Cell Binding Assays 
CHO cells were plated in triplicates of 10  s cells/well in 24-well 
plates (Nunc, Roskilde, Denmark) and used for binding assays 3 d 
later when the wells were fully confluent. Confluent CHO cells 
were washed twice with 1 ml of wash media (RPMI 1640 con- 
taining 2% FCS) and were pretreated with blocking mAbs at a 
1:100 or 1:50 dilution of ascites or 5-10 #g/ml of purified mAb 
for 15 min at 37~  30--45  x  106 Jurkat cells were labeled with 
0.8-1 mCi of SlCr (New England Nuclear, Boston, MA) for 1 h 
at 37~  washed twice in wash media, and 106 cells were added 
into each well and incubated for 90 min at 37~  Subsequently, 
cells were washed three to four times by gently dropping I ml of 
wash media each time to remove unbound cells, and cell-bound 
radioactivity was determined by lysing cells with 200 ~1 of 1% 
NP-40 solution and counting 180 #1 of each sample on a gamma 
counter. 
Results 
Construction and Expression of  a Pentameric  Form of  the Human 
CD2 Extracelhlar Segment.  In an initial effort to search for 
alternative ligands of CD2, we produced a recombinant mono- 
meric form of the  182-aa extrace!lular segment of CD2 in 
baculovirus (31) and subsequently in CHO cells (sCD2) (33). 
However, because the affinity (Ka) of monomeric sCD2 for 
the known ligand CD58 was only 0.4 #M, it was not pos- 
sible to develop a sensitive direct binding assay with either 
CD2  protein.  Consequently,  we herein produced a multi- 
meric CD2 protein to improve the avidity of the CD2 inter- 
action with its ligand(s). Since it is known that # heavy chains 
can associate into pentamers in the absence of Ig light chains (40), we produced a fusion protein between the human CD2 
extracdlular  segment  and  the  human  CHz-CH3-CH4  do- 
mains of/~ heavy chain in CHO cells using the plasmid termed 
pM2CD2IgM  depicted  in  Fig.  1  A  and  as  described  in 
Materials and Methods.  Recombinant protein was purified 
on an  anti-Till  mAb  affinity column  from culture  super- 
natants  containing  ,~4-5  /xg/ml  spCD2.  As  shown  by 
Coomassie staining of the reducing SDS-polyacrylamide gel 
in Fig.  1 B, the multimeric construct (spCD2) runs at ~90 
kD,  slightly larger than the/~ heavy chain that  migrates at 
"~80  kD.  In contrast,  the monomeric  182-aa  recombinant 
CD2 extracellular segment protein,  sCD2, migrates at *36 
kD. On nonreducing gels, spCD2 runs at *900 kD as com- 
pared with purified IgM, which migrates at *1,000 kD (Fig. 
1 B, inset). This mobility is consistent with the pentameric 
nature  of spCD2  and  the  IgM  molecule. 
Figure 1.  (.4)  pM2CD2IgM  expression  plasmid construct for produc- 
tion of spCD2 in CHO cells. Tllexz encodes aa 1-182 of human CD2. 
CH2, CH3, and CH4 encode the C region of domains 2, 3, and 4 of 
human ~t heavy  chain. (Ad2-mlp) Adenovirus 2 major late promoter and 
tripartite leader; (SV40-ori) DNA segment containing the SV40 origin 
of replication; (r polyA) polyadenylation  signal derived from the murine 
r light chain gene; (gpt) Escherichia  coli xanthine-guanine phosphoribosyl 
transferase gene. (B) SDS-PAGE  analysis  of spCD2. The above  indicated 
samples (1-3/~g) were  analyzed  by 7% polyacrylamide  gels  under reducing 
conditions and subsequently stained with Coomassie blue. (Inset) Indi- 
cated samples run under nonreducing conditions in a 3% polyacrylamide 
gal. (C) Binding ofbiotinylated  spCD2 and sCD2 toJY cells. The specific 
binding of the indicated  micromolar concentrations  of  biotinylated spCD2 
and sCD2 binding to JY cells was analyzed by flow cytometry using 
Streptavidin-FITC and measured as mean linear fluorescence  channel after 
subtracting background fluorescence  from ceils that were incubated with 
only Streptavidin-FITC. The binding of  biotinylated spCD2 (at 1 and 0.1 
#M) and sCD2 (at 10/xM) was specific  for CD58 as shown by the com- 
plete blockade  of detectable  fluorescence  by the anti-CD58 mAb (data not 
shown). 
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Enhanced Binding Efficiency of  Biotinylated spCD2 to B Lym- 
phoblastoid Cells and Survey of Hematopoietic Cell Lines for Re- 
activity.  A comparison of the binding of biotinylated spCD2 
and sCD2 to the JY B lymphoblastoid cell line was made 
by flow cytometric analysis after developing CD2-reactive cells 
with Streptavidin-FITC  and quantitating  staining by linear 
mean fluorescence.  As shown in Fig. 1 C, 10 #M monomeric 
sCD2 is required to achieve a clearly detectable binding pat- 
tern over the negative control stained with Streptavidin-FITC 
alone (linear mean fluorescence values). In contrast,  <1 nM 
spCD2 is required  to achieve  the same level of binding  on 
JY cells. The binding of spCD2 to cells was specific as judged 
by subsequent inhibition studies with sdected mAbs and pro- 
teins as described in Fig.  2. Similarly, the binding of sCD2 
to cells was specific as described in Table 1 (also see reference 
31).  These  results  unequivocally show  that  the  detectable 
binding efficiency ofbiotinylated spCD2 is substantially greater 
(by four orders of magnitude) than that of biotinylated sCD2 
for the CD2 ligand(s) on JY cells.  It is thus possible to use 
biotinylated spCD2 in sensitive direct binding assays to search 
for additional  CD2  ligands. 
As shown in Table 2, spCD2 reactivity on a panel of he- 
matopoietic cell lines correlated with the level of CD58 ex- 
pression  as judged by reactivity with  an  anti-CD58  mAb; 
the greater  the anti-CD58  mAb reactivity,  the greater  the 
spCD2 reactivity. B lymphoblastoid JY, SLA, and Arent calls, 
which express '~7-21-fold more CD58 compared with Daudi 
and  Raji cells,  show a comparable  "~9-27-fold  increase  in 
spCD2 reactivity. Similarly, erythroleukemic K562 ceils, which 
express  "~2.5-4.5-fold  more CD58 compared with  mono- 
cytic U937 and HL60 cells,  show a comparable two- to six- 
fold increase in  spCD2  reactivity. 
The Binding of  spCD2 and sCD2 to CIM8 +  CD58 +  CD59 + 
Cells Is Completely Blocked by Anti-CD58 mAh  We next con- 
ducted experiments on the B lymphoblastoid cell line JY using 
biotinylated spCD2 in the presence of various putative in- 
hibitors of CD2 binding, including sdected mAbs and recom- 
binant T cell surface proteins. As shown in Fig. 2, A-C, the 
JY cell line is reactive with anti-CD58, anti-CD48, and anti- 
CD59 mAbs. However, a 1:100 dilution of ascites containing 
the TS2/9 anti-CD58 mAb is sufficient by itsdf to completely 
block spCD2 binding (F vs. G). Complete blockade was also 
obtained with purified anti-CD58  mAb (data not  shown). 
This inhibition is specific to TS2/9 because neither an equiva- 
lent amount ofmAb directed against CD59 (H19 mAb) shown 
to block rosettes between human T cells and RBC (26) nor 
CD48 (6.28 mAb) expressed onJY ceils block spCD2 binding 
(H and/). Likewise, sCD4, a recombinant protein comprising 
domains  1 and 2 of the human  CD4 extracellular  segment 
(35),  does not inhibit  spCD2 binding  to JY cells,  whereas 
monomeric sCD2 (2 mg/ml) inhibits binding substantially 
(up to 83%; Fig. 2,J and K). The results of spCD2 binding 
suggest that CD2 does not interact directly with CD48 or 
CD59 expressed on JY cells.  Because the source of purified 
CD59 used by others to demonstrate CD2 binding in an in 
vitro plate assay was derived from human RBC (23), we tested 
the possibility that differential glycosylation of CD59 on JY 
cells vs. human RBC might contribute to the lack of CD2 
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Figure  2.  Flow  cytometric  analysis  of 
spCD2 binding to JY and human RBC in the 
presence of various inhibitors. JY and human 
RBC were incubated with the fonowing  mAbs: 
1:200 dilution of TS2/9 anti-CD58 ascites (.4 
and D), 10 #g/ml 6.28 anti-CD48 (B), and 10 
#g/ml  H19  anti-CD59  (C  and  E).  mAb 
binding  to cells was analyzed using  FITC- 
conjugated goat anti-mouse IgG. Background 
fluorescence  was obtained by staining cells with 
the control 11C5 mAb and the same second- 
step Ab. JY cells were preincubated with the 
following: media (F), 1:100 dilution of TS2/9 
anti-CD58 ascites (G), 1.2 mg/ml H19 anti- 
CD59  (/-/), 1 mg/ml 6.28 anti-CD48  (/), 2 
mg/ml sCD2  (J), and 2 mg/ml sCD4  (K). 
Human RBC preincubations were as follows: 
media (L), or 1:100 dilution of TS2/9 anti- 
CD58 ascites (M), 1.2 mg/ml H19 anti-CD59 
(N), and 1:100 dilution of control mAb 11C5 
ascites (O). After preincubation with the var- 
ious inhibitors  the  binding  of biotinylated 
spCD2 to JY and human RBC was assessed 
on a FACScan  |  using Streptavidin-FITC  as de- 
scribed in Materials and Methods. 
binding  to the former.  Therefore,  we next investigated  the 
binding  of biotinylated  spCD2  on  CD58 +CD59 +  human 
RBC (Fig.  2, D  and E) in the presence of anti-CD58  mAb 
TS2/9.  As shown  in  Fig.  2,  L  vs. M  and  O,  the binding 
of spCD2 is completely and selectively inhibited by TS2/9. 
The  H19  anti-CD59  mAb  does  not  block  the  binding  of 
spCD2 to human RBC (N). However, we could not, at this 
stage, exclude the possibility that H19 is directed at an epi- 
tope distinct from the CD2 binding site. Notwithstanding, 
these results collectively suggest that CD48 and CD59 mol- 
ecules expressed on human JY B  lymphoblastoid  cells and 
human  RBC  may not bind  CD2,  whereas  the  interaction 
between  CD2  and  CD58  molecules  is readily detected. 
Table  1.  Competitive Inhibition of Radioiodinated sCD2 
Binding to JY Cells 
Bound  to JY cells 
Although  it was conceivable that the spCD2 fusion pro- 
tein failed to adopt a native CD2 conformation required for 
CD48 and CD59 binding, this possibility seems remote since 
spCD2  reacts  with  anti-Till,  anti-T112,  and  anti-T113 
mAbs directed  at conformationally sensitive epitopes  (data 
not  shown).  Nevertheless,  to examine the  contribution  of 
CD58  to  CD2  binding  on  lymphoid  cells,  a  radiolabeled 
binding assay was used with sCD2 andJY cells. The binding 
of 12SI-sCD2 to JY cells was tested in the presence of either 
Table  2.  Reactivity of  Anti-CD58 mAb and spCD2 on Cell Lines 
Specific linear 
fluorescence intensity 
Anti-CD58  mAb  spCD2 
Cell line  Origin  reactivity  reactivity 
Inhibitor  Exp.  1  Exp.  2 
I~M  cpm 
sCD2 
0.025  46,310  +  752  35,122  +  446 
1.25  20,096  +  1,090  20,414  +  396 
12.5  14,059  +  651  14,673  +  358 
Anti-CD58  mAb  14,374  +  606  14,387  _+  132 
JY  B lymphoblastoid  85.0  39.6 
SLA  B lymphoblastoid  99.0  64.0 
Arent  B lymphoblastoid  87.1  24.2 
Daudi  B lymphoblastoid  4.8  2.4 
Karl  B lymphoblastoid  13.7  6.7 
K562  Erythroleukemic  16.8  11.2 
U937  Monocytic  6.9  5.9 
HL60  Myeloid  3.8  1.9 
JY cells were preincubated with either increasing micromolar concentra- 
tions of sCD2 or a saturating  1:50 dilution of anti-CD58 mAb ascites 
and competed with 0.125 I~M of 12SI-sCD2 (3.1  x  10  s cpm/nmol) at 
4~  for 1 h. Cells were pelleted by centrifugation and radioactivity  bound 
to the peleted cells was determined as described in Materials and Methods. 
Shown are mean and SD obtained from duplicate samples. 
The anti-CD58 mAb and spCD2 reactivity with various cell lines was 
analyzed by flow cytometry as described in Fig. 2. Specific mean linear 
fluorescence values for anti-CD58 and spCD2 reactivity were obtained 
by subtracting from the total linear fluorescence values the mean fluores- 
cence linear values obtained when cells were stained with control 11C5 
mAb or with only streptavidin-FITC,  respectively. 
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saturating amounts of anti-CD58 mAb. As shown in Table 
1, the binding of nSI-sCD2 is inhibited to the same level by 
both a 100-fold excess  of  unlabeled sCD2 and anti-CD58 mAb 
TS2/9, indicating that the binding of CD2 to JY cells is en- 
tirely through CD58. Therefore, by at least two indepen- 
dent assays using both pentameric and monomeric soluble 
CD2, we find that the only detectable surface CD2 ligand 
expressed on JY cells is CD58  as defined by TS2/9 mAb. 
Anti-CD58 mAb Does Not Crossreact with CD48 or CD59. 
The possibility that the TS2/9 anti-CD58 mAb might also 
crossreact with human CD48 and CD59 was tested on a set 
of CHO cell transfectants expressing selectively  CD58, CD48, 
CD59, or CD58 and CD59, termed CHO-CD58,  CHO- 
CD48, CHO-CD59, or CHO-CD58+59 cells, and an un- 
transfected control cell line, CHO. As shown in Fig. 3, the 
TS2/9 anti-CD58 mAb showed binding to CHO-CD58 (A) 
but not to CHO-CD48 cells (B), which express comparable 
levels of CD48 as judged by reactivity with the 6.28 anti- 
CD48 mAb (E). Incubation with a 100-fold higher concen- 
tration of anti-CD58 mAb still failed to detect reactivity with 
CHO-CD48 cells (data not shown).  These results indicate 
that the TS2/9 anti-CD58 mAb does not crossreact with the 
closely related CD48 molecule and that soluble CD2 binding 
to JY cells is restricted to CD58. In addition,  a direct anal- 
)'sis of CD2 binding to CD48 was conducted on CHO-CD48 
or control CHO-CD58 cells using the biotinylated spCD2 
binding assay. As shown by flow cytometric analysis (Fig. 
3, G, H, and/), under the standard washing condition uti- 
lized for mAb binding biotinylated spCD2 binds CHO-CD58 
but not CHO-CD48  or parental  CHO cells. 
As shown in Fig. 4, the TS2/9 anti-CD58 mAb binds only 
CHO-CD58 + 59 cells and showed no reactivity with CHO- 
CD59 cells, which bind two independent anti-CD59 mAbs, 
Anti- 
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CHO-CO58  CHO-CD48  CHO 
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Figure  3.  spCD2 binding to CHO-CD48  and CHO-CD58  transfec- 
tams. CHO cells or CHO cell transfectants were tested for their reactivity 
with TS2/9 anti-CD58  mAb (A-C),  6.28 anti-CD48 mAb (D-F),  and 
biotinylated spCD2 (G-0, and binding was analyzed on a FACScan  |  as 
shown in Fig.  2. 
H19 and YTH53.1 (Fig. 4, A, B, and E, and data not shown). 
This finding excludes  the possibility that the TS2/9 anti-CD58 
mAb crossreacts with CD59. Hence, the detectable binding 
of biotinylated spCD2  to CD58+CD59 + JY cells and hu- 
man KBC, which is blocked by anti-CD58 mAb, must be 
restricted to the cell surface CD58 molecule. Consistent with 
this notion was the further finding that spCD2 bound to 
CHO-CD58 + 59 but not CHO-CD59 transfectants (Fig. 4, 
C and H, respectively).  Neither a prolonged incubation period 
(overnight) nor alteration of incubation temperatures (4, 20, 
and 37~  results in detectable spCD2  binding to CHO- 
CD59 cells (data not shown). 
Human CD48 Is a Low A.~nity Ligand  for Human CD2.  A 
recent study using a mouse sCD2-Ig fusion protein revealed 
that the major ligand for mouse CD2 is CD48 (22). Since 
JY cells express human CD48 (Fig. 2) and the binding of 
spCD2  and  tzSI-sCD2 to JY  cells is  entirely blocked  by 
TS2/9  anti-CD58  mAb (which does not crossreact with 
CD48), this suggested to us that either CD48 is not a ligand 
or is a low affinity ligand for human CD2 that is not detect- 
able under these assay  conditions. We therefore used less strin- 
gent washing conditions as described  in Materials and Methods 
to detect any low affinity binding.  As shown in Fig. 5, top, 
under the latter condition, binding of spCD2  to CD58 as 
well as CD48 is detected (A and E) but no binding was de- 
tected to parental CHO cells (data not shown). The binding 
to CHO-CD58 and CHO-CD48 is specific  and can be blocked 
by an anti-Till F(ab')2 reactive with the CD2 adhesion do- 
main (domain 1) but not by an anti-T113 F(ab')2 directed at 
the membrane proximal domain (domain 2) (Fig. 5, top, B, 
C, F and G). The inhibition of spCD2 binding to CHO- 
CD48 by anti-Till F(ab')z suggests that the CD48 binding 
site on human CD2, like the CD58 binding site, is found 
on the adhesion  domain. Furthermore, as expected, the binding 
of spCD2 to CHO-CD58 and CHO-CD48 cells was blocked 
by anti-CD58 and anti-CD48 mAbs, respectively (Fig. 5, top, 
D  and H) but not by control mAbs (not shown). 
To determine the relative affinity of the CD2-CD48 in- 
teraction compared with the CD2-CD58 interaction, we con- 
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Figure  4.  spCD2 binding to CHO-CD58 + 59 and CHO-CD59  trans- 
fectants. The reactivity of CHO cells or CHO cell transfectants was tested 
for binding to TS2/9 anti-CD58 mAb (A-C), H19 anti-CD59 mAb (D-F), 
and biotinylated spCD2 (G--/), and binding was analyzed as shown in Fig. 2. 
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Figure 5.  spCD2 binding to CHO-CD48 and CHO-CD58 transfec- 
rants under  low stringency  wash conditions. ('/bp)  Binding  of  biotinylated 
spCD2 to CHO-CD48 and CHO-CD58 transfectants  was performed  under 
low stringency  wash conditions as described  in Materials and Methods. 
spCD2 was preincubated  with either media (A and E), anti-Tilt F(ab')2 
(B and F), or anti-T113  F(ab')z (C and G) before  addition to CHO trans- 
fectants, in D and H, ceils were preincubated  with either anti-CD58 or 
anti-CD48 mAb and then incubated  with biotinylated  spCD2. (Bottom) 
Analysis of relative  binding avidities  of  biotinylated  spCD2 to CHO-CD48 
and CHO-CD58 cells. The specific  binding of the indicated micromolar 
concentrations of biotinylated  spCD2 to CHO-CD48 and CHO-CD58 
cells was conducted  under low stringency  wash conditions and analyzed 
by flow cytometry.  Under these conditions, spCD2 showed no binding 
to the parental  CHO cells. Binding  was presented  as the linear  mean  fluores- 
cence channel as described in the legend for Fig. 2. 
ducted binding studies with various concentrations of spCD2 
on CHO-CD48 and CHO-CD58 cells expressing comparable 
levels of CD48 and CD58 molecules under the above low 
stringency conditions. As shown in Fig. 5, bottom, the rela- 
tive binding avidity of spCD2 for CD48 was about two orders 
of magnitudes lower than that for CD58. Thus, to achieve 
a readily detectable linear mean fluorescence value of 40 on 
the linear segment of the curves, 10 nM spCD2 was required 
for CHO-CD48  and  ",,0.2  nM  spCD2  was  required  for 
binding to CHO-CD58. Given the known micromolar affinity 
of the monomeric CD2-CD58 interaction and based on our 
assessment of the relative binding avidity of spCD2 for CD48 
and CD58, we estimate that the affinity (Ka) of monomeric 
CD2 for CD48 to be in the 10 -4 M  range. 
The Low Affinity CD2-CD48 Interaction Does Not Facilitate 
Adhesion between CD2 + T  Cells and CD48 + Cells.  As  a 
means of examining the functional relevance of the human 
CD2-CD48 interaction, we conducted binding studies using 
CD2 + Jurkat cells on CHO-CD48 and CHO-CD58 cells. 
5tCr-labded  CD2 + Jurkat  cells  failed  to  bind  to  CHO- 
CD48 cells and untransfected CHO cells but showed specific 
anti-CD2  (anti-T110  or  anti-CD58  mAb  inhibitable 
binding (>67%) to CHO-CD58 cells (Fig. 6). In contrast, 
anti-CD48 or anti-CD3 mAbs had no significant effect on 
the binding to CHO-CD58 cells. Given that anti-CD3 treat- 
ment is known to result in activation of  Jurkat cells, the latter 
observation is consistent with our previous study demon- 
strating that CD2-mediated adhesion is unaffected by intra- 
cellular signals that upregulate the adhesion function of other 
molecules (41). Therefore  our cell binding assay demonstrates 
that the low avidity human CD2-CD48 interaction is not 
sufficient to mediate adhesion between CD2 + T  cells and 
CD48 + cells,  Thus the physiologically relevant ligands for 
CD2 in the human  and mouse appear to be distinct. 
Human CD2 Does Not Bind to CD59-transfected CHO Cells. 
To detect any low affinity binding of CD2 to CD59, we used 
the same low stringency wash conditions for spCD2 binding 
to CHO-CD59 cells as used to detect low affinity binding 
of CD2 to CD48 (Ka ~10 -4 M). Under these conditions, 
spCD2 showed no binding to CHO-CD59 cells (data not 
shown). In addition, we conducted cell-based binding assays 
in  which  we  examined the  ability of StCr-labeled CD2 + 
Jurkat cells to bind to CHO cell transfectants. As shown in 
Fig  7,  CD2 § Jurkat  cells  showed  no  binding  to  CHO- 
CD59 cells as compared with untransfected CHO cells.  In 
8C 
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CHO  CHO-CD48  CHO-CD58 
Figure 6.  Binding  of CD2 § Jurkat cells to CHO-CD58 and CHO- 
CD48 transfectants. 10  ~  Jurkat cells labeled  with stCr were incubated  for 
I h at 37~  with the indicated  CHO cell  populations  in media  or pretreated 
with the designated  mAbs. At the end of this incubation, individual  wells 
were washed extensively  in wash media and binding of  Jurkat calls was 
detected by lysing adherent cells in a 1% NP-40 solution and counting 
radioactivity on a gamma counter. Results shown are representative  of 
three independent  experiments,  and the mean  and SD were  calculated  from 
triplicate samples. 
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fectants. The binding to the CHO-CD58+59 cells was de- 
pendent on the CD2-CD58 adhesion pair as judged by the 
>87% blockade with anti-CD2 (anti-Till) or anti-CD58 
(TS2/9) mAbs but no blockade by H19 anti-CD59 mAb (Fig. 
7). This was further substantiated in rosetting assays involving 
human thymocytes and CHO-CD58 + 59 and CHO-CD59 
cells in which rosetting was blocked  by anti-CD2  (anti- 
Tl11) and anti-CD58  (TS2/9) mAbs but not by the H19 
anti-CD59 mAb (data not shown). Thus, by two indepen- 
dent CD2 binding assays, it appears that CD59 is not a ligand 
for CD2. 
Discussion 
We have used a pentameric version of CD2 in which the 
entire extracellular segment of CD2 has been fused to CH2- 
CH3-CH4/~ heavy chain as a probe to detect CD2 ligands 
in hematopoietic cells, including B lymphoblastoid cell lines. 
The binding of biotinylated spCD2  to various cell popula- 
tions is directly correlated with their expression of CD58 
(Table 2). In particular, the binding of both spCD2 and 12sI- 
sCD2  to JY lymphoblastoid  cells was entirely blocked by 
TS2/9 anti-CD58 mAb, which suggests that the binding of 
CD2 to JY cells was restricted to CD58 (Fig. 2 and Table 
1). Since  JY cells also express comparable levels of CD48, 
the murine equivalent of which is a ligand of mouse CD2 
(22), and CD59, which has recently been reported to be a 
second ligand for CD2 (23, 24), we wondered if the TS2/9 
mAb crossreacted  with CD48 and CD59 and blocked spCD2 
binding to these molecules. Analysis of the binding of TS2/9 
anti-CD58 mAb to CD48- or CD59-transfected CHO cells 
showed no such crossreactivity (Figs. 3 and 4). Moreover, 
standard binding experiments with both biotinylated spCD2 
and CD2 § Jurkat cells show no detectable binding to CHO- 
CD48 or CHO-CD59 cells, while CD2 binding to control 
CHO-CD58 and CHO-CD58 + 59 cells is readily demon- 
CHO  CHO - CD59  CHO- CD58+  59 
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Figure  7.  Binding  of CD2 + Jurkat  cells  to  CHO-CD58+59  and 
CHO-CD59 transfectants. Binding of  Jurkat cells to individual CHO cell 
populations  pretreated with media or the indicated mAbs was conducted 
as shown in Fig. 6. Results shown are representative of three independent 
experiments. 
strated (Figs. 3, 4, 6, and 7). However, studies with spCD2 
under low stringency wash conditions  revealed binding to 
CHO-CD48 cells whereas no binding to CHO-CD59 cells 
was observed under any conditions  tested (Fig. 5, and data 
not shown). The affinity of the CD2-CD48 interaction com- 
pared with the CD2-CD58 interaction was "~  100-fold weaker 
and was estimated to be ~10 -4 M, consistent with the lack 
of conjugate formation between Jurkat cells and CHO-CD48 
cells. Collectively, our results indicate that the CD2-CD48 
interaction,  although conserved in the human, may be of 
limited physiological significance. 
Using a murine CD2-IgG chimera the ligand for CD2 
in the mouse has recently been identified as CD48 (BCM1) 
(22). Given the significant homology (31% aa identity) be- 
tween human CD58 and CD48 (21), we investigated whether 
human CD2 could bind to human CD48. Binding studies 
with biotinylated  spCD2  on CD48- or CD58-transfected 
CHO cells using less stringent washing conditions show that 
human CD48 is a low affinity ligand for human CD2. Based 
on the low affinity of CD2 for CD48, neither spCD2 under 
standard wash conditions  nor the monomeric sCD2  show 
any detectable binding to CD48 + JY cells in the presence 
of anti-CD58 mAb (Fig. 2 and Table 1). Since this low affinity 
binding does not result in the adhesion of CD2 + Jurkat cells 
to CHO-CD48 cells, we consider the interaction  of uncer- 
tain physiological significance, although we cannot rule out 
the possibility that at high copy number of CD2 and/or CD48 
some functional ceil-cell adhesion may occur. Of note, anti- 
CD3 mAb treatment, which is known to activateJurkat ceils 
and upregulate the adhesion function of other adhesion mol- 
ecules such as LFA-1 (41, 42), did not have any effect on the 
CD2-CD48 interaction (Fig. 6). Hence, it is likely that the 
low affinity interaction between human CD2 and CD48 is 
a consequence of the evolutionary divergence of ligands for 
cD2 
CD2 ~)__ 
CD48 
CD58 
Cell  Cell 
Membrane  Membrane 
Figure  8.  Illustration of the binding of CD2 to its known ligands. Based 
on the Ig-like structure  of CD2, which consists of two cxtracellular do- 
mains, and the significant similarity among primary amino acid sequences 
of CD2, CD48, and CD58, it is likely that these three receptors have similar 
tertiary structures.  The binding site on CD2 for CD58 is known to reside 
in the NH2-terminal  adhesion domain (domain  1). From mAb blocking 
studies, it appears that CD48 binds to this same CD2 domain.  The major 
CD2-based ligand binding interactions are shown on the bottom and top 
for human and mouse,  respectively. 
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quantitative binding studies show that the affinity of mouse 
CD2 for mouse CD48 is substantially higher than that be- 
tween the human homologues (data not shown). Hence it 
is likely that among the products of the CD2/CD48/CD58 
receptor gene family (Fig.  8), the mouse CD2-CD48 inter- 
action was largely replaced during evolution of the human 
species by the CD2-CD58 interaction. In conjunction with 
the data on murine system (22), these results provide among 
the first evidence that the major ligand-receptor pairs are dis- 
tinct in humans and mice. As the CD58 gene locus of the 
mouse is undefined at present, it is not yet clear whether 
CD58 is nonfunctional in the mouse or, alternatively, whether 
both murine CD48 and murine CD58 are ligands for mu- 
rine CD2.  This latter possibility is of interest, particularly 
in view of the restricted hematopoietic expression of CD48 
as contrasted with the more widespread distribution of CD58 
(8,  21,  28). 
Long-range restriction site analysis of a segment of human 
chromosome lp and the distal end of mouse chromosome 
3 encoding CD2  and ATPIA1  (Atpa-1)  genes reveals that 
they form syntenic pairs (43). Likewise, human chromosome 
lq and the distal end of mouse chromosome I encoding CD48 
and ATP1A2 (Atpa-3) genes are syntenic (44).  Hence, it is 
conceivable that a primordial gene segment duplicated to pro- 
duce a CD2 adhesion receptor/CD48 ligand recognition pair 
(whose genes show significant sequence homology both in 
humans and mice [44, 45]) before the divergence of humans 
and mice. Subsequently, during evolution, the CD2 gene may 
have diverged in these two species and its product evolved 
to recognize distinct ligands, CD58 and CD48, respectively. 
Because human CD58 is more homologous to human CD48 
than to human CD2 (21) and is also located on human chro- 
mosome 1 (46), it is likely that a further duplication of the 
CD48 gene gave rise to CD58 in the human whose product 
binds to CD2 with higher affinity. This duplication and diver- 
gence of the CD48 gene and its products may have also evolved 
to interact with a yet-to-be-identified ligand in the human. 
Based on the present study and that of Kato et al.  (22),  it 
would appear that the major ligands for CD2 in the humans 
and mice are distinct, even though human and mouse CD2 
and human and mouse CD48 are "~50% and 59% homolo- 
gous, respectively (44, 45). This is in contrast to other well- 
characterized lymphoid adhesion receptor/ligand interactions, 
including LFA-1/ICAM-1 (15, 47), CD4/class II MHC (48, 
49), CD8/class I MHC (50, 51), and CD5/CD72  (52,  53), 
where the interacting receptor/ligand pairs are conserved across 
the mouse and human species. Together, our study on CD2 
in the human and mouse systems shows that during evolu- 
tion primary structural homology between species may not 
always lead to conservation of a functional receptor ligand 
interaction across species. This consideration needs to be borne 
in mind when interpreting the recent unexpected observa- 
tion that thymocyte development is normal in CD2-/-  mice 
created by homologous recombination (54). 
The discrepancies in the literature regarding the interac- 
tion between CD2 and CD59 are yet to be fully resolved. 
An independent study of CD59  ligands using a chimeric 
CD59-IgG molecule revealed that the ligand for CD59 is 
primarily expressed on activated B lymphocytes and not found 
on either resting or activated T cells or T cell lines (55). Given 
the T cell-restricted tissue distribution of human CD2, these 
results are consistent with our finding that CD59 is not a 
CD2 ligand. In contrast to these results, two other recent 
studies suggest that CD59 is a second ligand for CD2.  In 
fact, Hahn et al.  (23) reported that the CD59 binding site 
is overlapping with, but distinct from, CD58. In that study, 
human CD2 transfectants of murine T cell hybridomas were 
shown to bind to plates coated with the 18-20-kD  CD59 
protein purified from human RBC. Because the binding of 
biotinylated spCD2 to both CD58+CD59 + JY cells as well 
as human RBC is completely blocked by anti-CD58 mAb, 
differential glycosylation of CD59 on RBC cannot account 
for the differences in results between our study and that of 
Hahn et al. (23). A second study by Deckert et al. (24) sug- 
gested that CD59 is a CD2 ligand based on the ability of 
anti-CD59 mAb, H19,  to block rosetting between human 
thymocytes, CD2-transfected thymoma cells, or CHO cells 
and human RBC or CD59-transfected CHO cells. However, 
the  percentage  of rosetting  cells  was  small  and  binding 
studies with 12SI-labeled soluble CD59 did not demonstrate 
saturable binding to CD2-expressing cells. The conflicting 
results reported in these studies are difficult to reconcile with 
our own. For example, even ifCD58 contaminated the CD59 
preparation used in the study by Hahn et al. (23), the differ- 
ence in CD2 binding sites for CD58 and CD59 as revealed 
by site-directed mutagenesis cannot be explained. Further- 
more, in both our study and that of Deckert et al. (24), H19 
mAb was used with differing results. However, it is possible 
that binding of CD2  to CD59  is dependent on an as yet 
undefined T cell structure (X) that may be absent from Jurkat 
cells used here, and, hence, would not be detected in either 
our cell-based or soluble CD2 assay. If that were the case, 
then given the reports by Hahn et al.  (23)  and Deckert et 
al. (24),  X must be present on CHO ceils as well as murine 
T  cell hybridomas, two disparate cell types from divergent 
species. We believe this explanation to be unlikely as we also 
observed no specific (i.e., blockable with an anti-CD59 mAb) 
rosettes between human thymocytes and CD59 CHO cell 
transfectants. 
In summary, we have developed a pentameric version of 
CD2, spCD2, and used this in sensitive flow cytometric anal- 
ysis to define alternative ligands for CD2. This analysis com- 
bined with more physiological, cell-based adhesion assays in- 
volving CD2 + T  cells  and CD59-expressing cells indicate 
that CD2 does not bind CD59. Furthermore, using spCD2 
we identify that human CD48 is a low affinity ligand for 
human CD2 and has an estimated binding constant that is 
50-100-fold less avid than that of CD58. Moreover, our cell- 
based adhesion assay using CD2 + Jurkat cells and CD48- 
or CD58-expressing CHO cells shows that there is no adhe- 
sion mediated by the CD2-CD48  interaction and provides 
evidence that the major ligands for CD2 in humans and mice 
are distinct. Collectively, our findings indicate that the major 
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teraction is CD58. We also note that the sulfated polysaccha- 
ride dextran sulfate, which has been shown to bind human 
CD2, may be involved in the binding of CD2 to additional 
ligands (56). Using the spCD2-based binding assay, it should 
now be possible to test if additional ligand(s) for human CD2 
distinct from CD58 exist on other cell types either constitu- 
tively or upon activation. 
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